← back to search

David Meriwether

University of California, Los Angeles · US
Area of research
Clinical Biochemistry · Surgery
Research interest
Research interests include Paraoxonase enzyme and polymorphisms, Cholesterol and Lipid Metabolism, Inflammatory mediators and NSAID effects, and Eicosanoids and Hypertension Pharmacology.
h-index
20
citations
1,276
works
56
NIH funding
primary concept
email

Recent publications

Macrophage COX2 Mediates Efferocytosis, Resolution Reprogramming, and Intestinal Epithelial Repair
Cellular and Molecular Gastroenterology and Hepatology 2022cited by 61position: firstdoi
Iron loading induces cholesterol synthesis and sensitizes endothelial cells to TNFα-mediated apoptosis
Journal of Biological Chemistry 2021cited by 34position: middledoi
Apolipoprotein A-I mimetics mitigate intestinal inflammation in a COX2-dependent inflammatory disease model
Journal of Clinical Investigation 2019cited by 90position: firstdoi
Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum
Journal of Lipid Research 2017cited by 13position: middledoi
Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux
Journal of Lipid Research 2016cited by 22position: firstdoi
Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis
Journal of Lipid Research 2015cited by 49position: middledoi
A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion
PLoS Pathogens 2013cited by 114position: middledoi
A novel approach to oral apoA-I mimetic therapy
Journal of Lipid Research 2013cited by 93position: middledoi
Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid
Journal of Lipid Research 2013cited by 67position: middledoi
HDL Mimetics Inhibit Tumor Development in Both Induced and Spontaneous Mouse Models of Colon Cancer
Molecular Cancer Therapeutics 2012cited by 72position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Srinivasa T. Reddy · University of California, Los Angeles9 papers (2012–2022)Alan M. Fogelman · University of California, Los Angeles8 papers (2012–2022)Víctor Grijalva · University of Wisconsin–Madison7 papers (2012–2022)Mohamad Navab · University of California, Los Angeles5 papers (2012–2017)G.M. Anantharamaiah · University of Alabama at Birmingham5 papers (2013–2019)Alan C. Wagner · University of California, Los Angeles4 papers (2013–2016)A. Chattopadhyay · Indian Statistical Institute4 papers (2013–2017)Greg Hough · Cidara Therapeutics (United States)4 papers (2013–2017)Feng Su · Central South University4 papers (2012–2015)Robin Farias‐Eisner · Creighton University3 papers (2012–2013)Carmen Volpe · UCLA Health2 papers (2016–2019) · 2 papers (2015–2016)Aldons J. Lusis · ABT Molecular Imaging (United States)2 papers (2013–2017)Dawoud Sulaiman · University of California, Los Angeles2 papers (2016–2019)Martı́n G. Martı́n · University of California, Los Angeles2 papers (2019–2022)Steven J. Bensinger · UCLA Medical Center2 papers (2016–2017)Nasrin Dorreh · University of Wisconsin–Madison2 papers (2019–2022)Kym F. Faull · University of California, Los Angeles2 papers (2015–2017)Kevin J. Williams · University of Michigan2 papers (2016–2017)Harvey R. Herschman · University of California, Los Angeles2 papers (2019–2022)